PMGC Holdings Inc.
For the period ended Nov 1, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 1, 2026 · Filed Nov 5, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Next Steps for the EL-32 Program
Next Steps for the EL-32 Program
The study accomplished its purpose as a proof-of-concept experiment, generating the first controlled in vivo data on EL-32 in a GLP-1 combination setting and identifying the dose and endpoints that merit further study. While semaglutide was responsible for the majority of observed weight loss and metabolic improvements, the contract research organization noted that the semaglutide dose used produced substantial effects on its own, leaving a limited window to detect an additional effect of EL-32, and recommended that the combination be re-evaluated with a lower dose of semaglutide.
Based on these findings, NorthStrive plans to design a follow-on preclinical study evaluating EL-32 in combination with a lower dose of semaglutide, with lean mass and body composition considered to be the primary endpoints, and expects to provide an update on the design and timing of that study in the first quarter of 2027. The results will also inform NorthStrive’s broader EL-22 and EL-32 development program, including the analytical characterization work with Charles River Laboratories announced on September 29, 2026 and the planned spaceflight study under the Orbit2Orbit term sheet announced on August 25, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.